CN108712902A - 脂肪乳剂、及其制造方法、提高脂肪乳剂的稳定性的方法、以及脂肪乳剂的稳定性提高剂 - Google Patents

脂肪乳剂、及其制造方法、提高脂肪乳剂的稳定性的方法、以及脂肪乳剂的稳定性提高剂 Download PDF

Info

Publication number
CN108712902A
CN108712902A CN201780001246.2A CN201780001246A CN108712902A CN 108712902 A CN108712902 A CN 108712902A CN 201780001246 A CN201780001246 A CN 201780001246A CN 108712902 A CN108712902 A CN 108712902A
Authority
CN
China
Prior art keywords
fat emulsion
histidine
content
mass
flurbiprofen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780001246.2A
Other languages
English (en)
Chinese (zh)
Inventor
天野阳平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kewpie Corp
Original Assignee
Kewpie Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kewpie Corp filed Critical Kewpie Corp
Priority to CN202410386072.8A priority Critical patent/CN118415981A/zh
Publication of CN108712902A publication Critical patent/CN108712902A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)
  • Cosmetics (AREA)
CN201780001246.2A 2017-02-07 2017-05-08 脂肪乳剂、及其制造方法、提高脂肪乳剂的稳定性的方法、以及脂肪乳剂的稳定性提高剂 Pending CN108712902A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410386072.8A CN118415981A (zh) 2017-02-07 2017-05-08 脂肪乳剂、及其制造方法、提高脂肪乳剂的稳定性的方法、以及脂肪乳剂的稳定性提高剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017-020377 2017-02-07
JP2017020377 2017-02-07
PCT/JP2017/017378 WO2018146829A1 (ja) 2017-02-07 2017-05-08 脂肪乳剤、及びその製造方法、脂肪乳剤の安定性を向上させる方法、並びに脂肪乳剤の安定性向上剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410386072.8A Division CN118415981A (zh) 2017-02-07 2017-05-08 脂肪乳剂、及其制造方法、提高脂肪乳剂的稳定性的方法、以及脂肪乳剂的稳定性提高剂

Publications (1)

Publication Number Publication Date
CN108712902A true CN108712902A (zh) 2018-10-26

Family

ID=63108143

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780001246.2A Pending CN108712902A (zh) 2017-02-07 2017-05-08 脂肪乳剂、及其制造方法、提高脂肪乳剂的稳定性的方法、以及脂肪乳剂的稳定性提高剂

Country Status (5)

Country Link
JP (1) JP6550175B2 (ko)
KR (2) KR20190110563A (ko)
CN (1) CN108712902A (ko)
TW (1) TWI803478B (ko)
WO (1) WO2018146829A1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113952299A (zh) * 2020-07-15 2022-01-21 丘比株式会社 乳液、注射剂和制备乳液的方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109223712B (zh) * 2018-10-10 2020-06-02 武汉大安制药有限公司 氟比洛芬酯注射用乳剂及其制备方法
CN112545980A (zh) * 2019-09-25 2021-03-26 北京普德康利医药科技发展有限公司 低含量氟比洛芬酯药物组合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102988291A (zh) * 2012-12-13 2013-03-27 哈药集团技术中心 一种氟比洛芬酯脂肪乳注射液组合物及其制备方法
CN105106115A (zh) * 2015-10-10 2015-12-02 北京蓝丹医药科技有限公司 一种稳定的丙泮尼地脂肪乳

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0543450A (ja) * 1991-08-09 1993-02-23 Green Cross Corp:The 凍結乾燥製剤
JPH0881360A (ja) * 1994-07-13 1996-03-26 Wakamoto Pharmaceut Co Ltd 安定な脂肪乳剤
US5693337A (en) * 1994-07-13 1997-12-02 Wakamoto Pharmaceutical Co., Ltd. Stable lipid emulsion

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102988291A (zh) * 2012-12-13 2013-03-27 哈药集团技术中心 一种氟比洛芬酯脂肪乳注射液组合物及其制备方法
CN105106115A (zh) * 2015-10-10 2015-12-02 北京蓝丹医药科技有限公司 一种稳定的丙泮尼地脂肪乳

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
宋华先等: "磷脂中微量组分对载药脂肪乳质量的影响", 《中国新药杂志》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113952299A (zh) * 2020-07-15 2022-01-21 丘比株式会社 乳液、注射剂和制备乳液的方法
US12611410B2 (en) 2020-07-15 2026-04-28 Kewpie Corporation Emulsion, injection agent, and emulsion preparation method

Also Published As

Publication number Publication date
TW201828935A (zh) 2018-08-16
WO2018146829A1 (ja) 2018-08-16
JP2018150387A (ja) 2018-09-27
TWI803478B (zh) 2023-06-01
KR20190110563A (ko) 2019-09-30
KR20210132228A (ko) 2021-11-03
JP6550175B2 (ja) 2019-07-24
KR102421538B1 (ko) 2022-07-14

Similar Documents

Publication Publication Date Title
CN101511367B (zh) 前列腺素脂肪乳剂及其制造方法、以及其稳定化方法及乳化剂
JP5886273B2 (ja) プロゲストーゲンを含む低含油薬学的エマルジョン組成物
CN108712902A (zh) 脂肪乳剂、及其制造方法、提高脂肪乳剂的稳定性的方法、以及脂肪乳剂的稳定性提高剂
US20250186536A1 (en) Sustained release peptide formulations
Pham et al. In vivo formation of cubic phase in situ after oral administration of cubic phase precursor formulation provides long duration gastric retention and absorption for poorly water-soluble drugs
WO2012133554A1 (ja) プロスタグランジン含有脂肪乳剤
CN103622907B (zh) 一种布洛芬脂肪乳注射液及其制备方法
CN106137963A (zh) 抗心律失常药物脂肪乳注射液及其制备方法
WO2021031791A1 (zh) 一种右布洛芬脂肪乳注射液及其制备方法
JP6368862B1 (ja) 脂肪乳剤、及びその製造方法、脂肪乳剤の安定性を向上させる方法、並びに脂肪乳剤の安定性向上剤
WO2011145660A1 (ja) プロポフォール含有水中油型エマルション組成物
CN115400078A (zh) 一种塞来昔布乳状注射液及其制备方法
JP6076520B2 (ja) プロスタグランジン含有脂肪乳剤
JP2013001700A (ja) プロポフォール含有水中油型エマルション組成物
JP2012214430A (ja) プロスタグランジン含有脂肪乳剤
WO2019230964A1 (ja) 容器詰水中油型乳化組成物
CN107412160B (zh) 一种含前列腺素的脂肪乳剂及其制备方法
JP2024065470A (ja) エマルジョン、及びその製造方法
HK1143039A (en) Pyrazolone derivative emulsion formulations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20181026